Patient-Specific Pluripotent Stem Cells in Neurological Diseases

Table 2

iPSC-based cell-replacement therapy in preclinical animal models of neurological diseases.

Disease	Species	Model	Transplanted cells	Delivery route	Outcome	Reference
PD	Rat	6-OHDA	mbDA PGCs derived from hiPSCs	Transplantation	Long-term survival; Differentiation to DA neurons; Tumor-like cells at the site of graft	Cai et al. [108]
	Rat	6-OHDA	PD patient iPSC- derived DA neurons	Transplantation	Improved motor behavior	Hargus et al. [109]
	Rat	6-OHDA	iPSC-derived DA neurons	Transplantation	Improved motor behavior	Wernig et al. [110]
	Rat	6-OHDA	iPSC-derived DA neurons	Transplantation	Improved motor behavior	Swistowski et al. [19]
Stroke	Rat	MCAO	iPSCs + FG	Direct injection to infarct area/subdural	Decreased infarct size; Improved motor performance; Decreased inflammatory cytokines	Chen et al. [111]
	Mouse	MCAO	Mouse iPSCs	Transplantation	Tridermal tumorigenesis	Kawai et al. [112]
	Mouse	MCAO	Mouse iPSCs	Transplantation	Increased teratoma risk and volume; Increased MMP9 and pVEGFR2	Yamashita et al. [113]
SCI	Mouse	Contusion model	iPSC-derived neurospheres	Transplantation (contusion area)	Remyelination and functional recovery	Tsuji et al. [114]

6-hydroxydopamine (6-OHDA), dopaminergic (DA), fibrin glue (FG), induced-pluripotent stem cell (iPSC), matrix metalloproteinase-9 (MMP9), midbrain (mb), middle cerebral artery occlusion (MCAO), Parkinson’s disease (PD), phosphorylated vascular endothelial growth factor receptor2 (pVEGFR2), progenitor cell (PGC), and spinal cord injury (SCI).